This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

In review of CRISPR patent interference, US panel says board legally erred

( May 12, 2025, 19:09 GMT | Official Statement) -- MLex Summary: A determination of priority by the Patent Trial and Appeal Board in interference proceedings between an issued patent and a patent application directed to CRISPR-Cas9 gene editing must be revisited, the US Court of Appeals for the Federal Circuit ruled.  The board wrongly found that the Regents of the University of California, the University of Vienna, and Emmanuelle Charpentier were required to demonstrate knowledge that their invention would work at the time their application was filed in order to be entitled to priority, according to the Federal Circuit.See attached document....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections